(NU/1433-47) Kargenera: The Provision of Business Consultancy to Assist Commercialisation of University Research
Estimated value
—
services
Awarded value
—
Suppliers
1
1 SME
Lots
1
1 awarded
Published
06 Feb 2023
Description
The University of Southampton have developed a unique DNA based therapeutic to activate NK cells against cancer. The therapeutic is delivered intramuscularly in combination with DNA encoding the potent immune stimulating cytokine IL-15. The objective is for an Executive to jointly work with the team to bring the opportunity towards and ultimately achieve launch of a new spinout company.
Scope
- Reference
- DN644002
- Commercial tool
- Standalone contract
- Main category
- services
- Contract locations
- North East England
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Ability to meet the required programme | Pass/Fail | quality | — |
| Ability to meet the Job Description | Pass / Fail and Weighted 60% | quality | — |
| Formal Appointment as CEO | Pass/Fail) | quality | — |
| Equity | 15% | quality | — |
| — | 25% | price | — |
Submission & procedure
- Procedure
- Restricted procedure
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Awarded to